068330 — Ilshinbiobase Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapContrarian

Annual income statement for Ilshinbiobase Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS/A	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24,379	20,433	16,437	10,818	14,530
Cost of Revenue
Gross Profit	12,657	10,510	9,428	6,278	7,722
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	17,042	16,015	10,223	8,556	9,984
Operating Profit	7,337	4,418	6,214	2,262	4,546
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	7,816	4,704	7,755	4,628	5,864
Provision for Income Taxes
Net Income After Taxes	5,858	3,815	6,232	3,812	4,793
Net Income Before Extraordinary Items
Net Income	5,858	3,815	6,232	3,812	4,793
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,858	3,815	6,232	3,812	4,793
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	137	103	148	91.5	115
Dividends per Share